home
Number
Title
Author
Date
29
HLB to merge with US anticancer drug company LSK BioPharma
admin
2019.06.13
28
LSK BIOPHARMA AND JIANGSU HENGRUI MEDICINE ANNOUNCE FDA CLEARANCE TO INITIATE A PHASE 3 CLINICAL TRIAL IN ADVANCED HEPATOCELLUL
admin
1970.01.01
27
ASCO-SITC Clinical Immuno-Oncology Symposium 2019 Poster of Rivoceranib AM107 Study
admin
1970.01.01
26
LSKB ANNOUNCES THAT THE ANGEL STUDY HAS REACHED ITS PRIMARY COMPLETION DATE
admin
1970.01.01
25
LSK BIOPHARMA TO ATTEND AND PRESENT AT THE ASCO 2017 ANNUAL MEETING
admin
1970.01.01
24
THE US FDA GRANTS APATINIB ORPHAN DRUG DESIGNATION FOR TREATMENT OF GASTRIC CANCER
admin
1970.01.01
23
LSK BIOPHARMA ANNOUNCES STARTING OF SITE INITIATION VISITS IN THE U.S. FOR ITS PHASE 3 GASTRIC CANCER TRIAL STUDYING APATINIB
admin
1970.01.01
22
REGULATORY AFFAIRS ASSOCIATE November 9, 2018News JOB DESCRIPTION Responsible for compliance with applicable procedures. This
admin
1970.01.01
21
LSKB TO REPORT NON-CLINICAL RIVOCERANIB (APATINIB) COMBINATION WITH IMMUNOTHERAPY
admin
1970.01.01
20
LSKB ANNOUNCES OFFICIAL NONPROPRIETARY NAMING OF APATINIB (YN968D1): RIVOCERANIB
admin
1970.01.01